Late Breaking Abstract - TriOptimize VIII – Improvement of Lung Function with Extrafine Single Inhaler Triple Therapy – Analysis of Response Patterns by Prior Treatment from a Real-World Study. Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020
A Study on Various Types of Presentations of Paediatric Tuberculosis and Response to Fixed Dose Combination (FDC). Source: Virtual Congress 2020 – The young, the old and extrapulmonary tuberculosis Year: 2020
BREEZE: Open-label, Clinical Study to Evaluate the Safety and Tolerability of a Treprostinil Dry Powder Inhaler in Patients with Pulmonary Arterial Hypertension Currently Using Tyvaso Source: Virtual Congress 2021 – Therapy of pulmonary hypertension Year: 2021
LATE-BREAKING ABSTRACT: TITLE: Hypertonic Saline in Acute Bronchiolitis: Randomised Controlled Trial (RCT) and Economic Evaluation (The SABRE Study) Source: International Congress 2014 – Prevention, diagnosis and consequences of respiratory infections in children Year: 2014
Cost Effectiveness Comparison of a Dry Powder Inhaler to a Metered Dose Inhaler plus Valved Holding Chamber based on a Functional Respiratory Imaging (FRI) Model Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence Year: 2021
Understanding of Pharmacokinetics and Exposure Drives use of Nintedanib as a Positive Control Reference Item in a Rat Model of Bleomycin-Induced Fibrosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019
Cardiovascular (CV) safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three Phase III studies Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014
Late Breaking Abstract - Lung deposition of two different ICS/LABA combinations with Dry Powder Inhaler (DPI) in asthmatic patients using Functional Respiratory Imaging (FRI). Source: International Congress 2019 – Imaging for prognostication and disease characterisation: 2019 update Year: 2019
Late Breaking Abstract - SUPRAnav: A Clinical Trial Evaluating the Efficacy and Safety of a New Invention Device Designed for Continuous Supraglottic Aspiration in Mechanically Ventilated Patients. Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Intensive care and infection Year: 2019
Curcumin Improves Therapy of Moderate Partially Controlled Asthma: Placebo-controlled, single blind study Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Late Breaking Abstract - Real-World Characteristics of Patients Receiving Dupilumab in Routine Clinical Practice in a Multinational, Non-Interventional Study (ProVENT) Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Using Step Count to Enhance Daily Physical Activity in PH, a pilot-study (STEP in PH). Source: International Congress 2019 – Pulmonary arterial hypertension: recent advances from the bedside Year: 2019
Comparison of Treprostinil Palmitil Inhalation Suspension (TPIS) or Oral Sildenafil (Sild) in a Sugen/Hypoxia Rat Model of PAH. Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020
Late Breaking Abstract - Two Phase 3 Randomized Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist, in Refractory or Unexplained Chronic Cough (COUGH-1 and COUGH-2) Source: Virtual Congress 2020 – ALERT: Pneumothorax, cough, PAH, alveolar proteinosis Year: 2020
Late Breaking Abstract - Comparative Effectiveness of Anti-IL5/5R Versus Anti-IgE in Patients Eligible for Both (FIRE) Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021
The IMPACT Trial: Single Inhaler Triple Therapy vs dual therapies: Efficacy across multiple COPD endpoints over time Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Patient preference for COPD treatment inhalers: A Discrete Choice Experiment (DCE) in France – Results of a Pilot Study Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018
Dupilumab (DPL) Improves Upper and Lower Airway Outcomes in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) with Nonsteroidal Anti-inflammatory Drug-Exacerbated Respiratory Disease (NSAID-ERD): Pooled Results From SINUS-24, SINUS-52 Phase 3 Trials Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019
Safety and Tolerability of Combination Therapy with Nintedanib and Pirfenidone for Idiopathic Pulmonary Fibrosis: A Multicenter, Retrospective, Observational Study in Japan Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020
Late Breaking Abstract - Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF) Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension Year: 2019